



Edward R.T. Tiekink 
Research Centre for Crystalline Materials, School of Science and 
Technology, 5 Jalan Universiti, Sunway University, Bandar Sunway, 




Racemic crystals normally crystallise in centrosymmetric space-
groups containing equal numbers of enantiomers.  More rarely, race-
mates may crystallise in non-centrosymmetric space-groups having 
glide symmetry or, even more rarely, in space-groups devoid of a cen-
tre of inversion, having no rotary-inversion axes nor glide plane.  The 
latter class of crystals form the subject of the present bibliographic 
review – a survey of kryptoracemic behaviour.  The term kryptorace-
mic alludes to the presence of a hidden or non-crystallographic centre 
of inversion between two molecules that might otherwise be expected 
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to crystallise in an achiral space-group, often about a centre of inver-
sion.  Herein, examples of molecules with stereogenic centres crystal-
lising in one of the 65 Sohncke space-groups are described.  Genuine 
kryptoracemates, i.e. crystals comprising only enantiomorphous pairs 
are described followed by an overview of non-genuine kryptorace-
mates whereby the crystal also contains other species such as solvent 
and/or counterions.  A full range, i.e. one to six, stereogenic centres 
are noted in genuine kryptoracemates.  Examples will also be de-
scribed whereby there are more that one enantiomeric pair of mole-
cules in the crystallographic asymmetric unit.  A more diverse range 
of examples are available for non-genuine kryptoracemates.  There 
are unbalanced species where in addition to the enantiomeric pair of 
molecules, there is another enantiomeric molecule present.  There are 
examples of genuine co-crystals, solvated species and of salts.  Fi-
nally, special examples will be highlighted where the counterions are 
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26.1 Introduction 
The intriguing term kryptoracemate has been ascribed [1] to Ivan 
Bernal, a renowned chemical crystallographer with a particular inter-
est in chirality in crystals especially in metalorganic systems.  It is 
understood that Ivan Bernal employed the term during a meeting of 
the American Crystallographic Association in the mid-1990’s [2].  
Clearly, the term refers to the crystallisation of racemic compounds.  
Less obvious is the origin of the prefix “krypto”, which comes from 
the Greek and loosely translates as hidden.  Thus, kryptoracemic be-
haviour refers to crystallisation of racemic molecules about a hidden, 
i.e. a non-crystallographic, centre of inversion.  For organic mole-
cules, the most recent comprehensive review of the topic by Fábián 
and Brock [3] highlights how rare this phenomenon is, accounting for 
only 0.1% of all-organic structures included in the Cambridge Struc-
tural Database (CSD) [4]; a complimentary survey of kryptoracemic 
behaviour in metalorganic systems has been published by Bernal and 
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Watkins [5].  The aim of the present Chapter is to alert the reader to 
this crystallographic peculiarity by surveying the structural character-
istics of representative examples of all-organic molecules known with 
a certain degree of confidence to exhibit kryptoracemic behaviour. 
There are at least three possible outcomes from the crystalli-
sation from a solution of a racemic compound.  In descending order 
of importance, these crystallisation outcomes are: i) an ordered race-
mic crystal, ii) a physical mixture comprising equal numbers of enan-
tiopure crystals and iii) a kryptoracemate; herein, solid-solutions and 
enantiomorphous twins are ignored.  Racemic compounds have equal 
numbers of the enantiomers in the crystal, i.e. an equal distribution of 
mirror images of the molecules.  This is normally accomplished by 
having the molecules disposed about a crystallographic centre of in-
version.  There are exceptions to this general principle whereby a 
racemate can crystallise in a non-centrosymmetric space-group, but a 
space-group having glide symmetry so that the criterion of having 
equal numbers of mirror images pertains.  An early survey of this later 
phenomenon by Dalhus and Görbitz [6] revealed that 90% of crystals 
in this category crystallised in five non-centrosymmetric space-
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groups, namely Pc, Cc, Pca21, Pna21 and Fdd2.  The second phenom-
enon leading to a physical mixture of crystals, or a conglomerate of 
homo-chiral crystals, is usually termed spontaneous resolution and 
was famously recognised by Pasteur in his work on ammonium so-
dium tartrate crystals [7].  The third crystallisation outcome for race-
mic compounds results in kryptoracemic crystals which are charac-
terised as crystallising in space-groups lacking a centre of inversion, 
mirror planes and rotary-inversion centres, i.e. not having symmetry 
operators of the second kind, as discussed further below. 
 The reality is that most organic materials containing a pair of 
resolvable isomers (also those with meso symmetry and achiral com-
pounds) crystallise in one of the centrosymmetric space-groups lead-
ing to hetero-chiral crystals; this has been termed an enantiophilic trait 
[8].  It is estimated that 99% of molecules (neutral and charged) that 
can crystallise in a centrosymmetric space-group, will do so [9].  This 
is probably related to close-packing considerations: it is well estab-
lished that 83% of all structures included in the CSD [4] crystallise in 
one of six space-groups out of a possible 230 space-groups (or 219 
when the 11 pairs of enantiomorphic space-groups are counted once 
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only), i.e. P21/c (34.6%), P1̄ (24.5%), C2/c (8.4%), P212121 (7.2%), 
P21 (5.2%) and Pbca (3.3%), or alternative settings of these [9, 10].  
The common feature of the indicated space-groups is that they are all 
are conducive to close-packing arrangements, which is optimised for 
spherical molecules.  Thus, an odd-shaped molecule crystallising 
about a centre of inversion inherently becomes more spherical in 
shape.  When, enantiophilic behaviour [8] no longer prevails, enanti-
ophobic behaviour comes to the fore resulting in the formation of con-
glomerates or, more rarely, kryptoracemates. 
 In terms of space-group symmetry, kryptoracemates are re-
stricted in the adoption of these.  As mentioned above, kryptorace-
mates can only crystallise in space-groups not having symmetry op-
erators of the second kind.  Thus, a kryptoracemate must crystallise 
in one of the 65 Sohncke space-groups (non-enantiogenic groups) 
which are characterised as not having a centre of inversion, rotary-
inversion axes or glide planes, i.e. only have symmetry operations of 
the first kind; crystals adopting Sohncke space-groups are chiral.  Fur-
ther, the number of molecules in the crystallographic asymmetric unit, 
i.e. Z′ (equals the number of formula units in a unit cell divided by the 
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number of general positions for that unit cell) is greater than unity 
unless the molecule itself lies on a rotation axis [11]. 
 The purpose of this overview is not to give a comprehensive 
list of all known kryptoracemates but, rather highlight the different 
classes of kryptoracemates that have been described in the crystallo-
graphic literature.  As a starting point, a clarification of the term kryp-
toracemic compound is made, analogous to that now adopted for su-
pramolecular isomers [12, 13].  A supramolecular isomer (SI) is a 
molecule/framework that can adopt a different structure, including 
with different atomic connectivity, as opposed to a polymorph [14].  
Often, this phenomenon was accompanied by a change in the counter-
ion and/or solvent occluded in the crystal [12].  Subsequently, the 
term was modified to refer to a genuine SI [13], whereby the molecu-
lar formula was exactly the same, rather than the generic, all-encom-
passing SI [12].  Thus, herein, kryptoracemates are divided into “gen-
uine kryptoracemates”, with only one type of species (molecule or 
zwitterion) in the crystal, and “more loosely-defined kryptorace-
mates”, which may include counter-ions, solvent, etc. in their crystals. 
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 With the above division in mind, the following survey is ar-
ranged in terms of the number of chiral centres in the molecule and 
highlights different issues associated with the examples, for example, 
polymorphism, the availability of crystals of diastereoisomers, etc.  
The images herein are original, being generated from the Crystallo-
graphic Information Files (CIF’s) [15] available through the CSD [4] 
employing DIAMOND [16] and Qmol [17].  The chemical diagrams 
were drawn with ChemDraw™ and data analysis was aided by Mer-
cury [18] and PLATON [19].  The respective CSD [4] REFCODES 
are included in the captions to the figures.  Finally, while common 
names are employed in the text as much as possible, IUPAC names 
are included in the captions to the figures, as determined by 
MarvinSketch [20]. 
 
26.2 Genuine kryptoracemates 
A distinction is made herein between genuine and non-genuine 
kryptoracemates.  While the basic definition is the same for both clas-
ses of compound, the influence of solvent or a counterion on the crys-
tallisation outcome is virtually impossible to determine with absolute 
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confidence.  Hence, kryptoracemic crystals comprising enantiomor-
phic molecules are discussed first; in 26.3, kryptoracemic crystals 
having additional species present in the crystal will be described. 
One of the very first molecules to exhibit kryptoracemic be-
haviour was DL-2-hydroxyphenylalanine (1), which, in fact crystal-
lises as a zwitterion [21]; images for 1 are shown in Figure 26.1.  
There is one stereogenic centre in 1, which crystallises in the mono-
clinic space-group P21 with Z′ = 2, the asymmetric unit comprising a 
pair of ostensibly enantiomorphic molecules; the S form is shown in 
Figure 26.1.  The overlap diagram, comprising the S-form and in-
verted R-form display an almost perfect overlap, as is often seen in 
kryptoracemates.  However, in this case, the diagram is misleading.  
The enantiomeric molecules are related by a non-crystallographic 
centre of inversion located at 0.661, 0.390, 0.802.  As the fractional 
atomic coordinates for the R-form were not available, this molecule 
was generated arbitrarily.  While 1 is zwitterionic, the overwhelming 
majority of genuine kryptoracemates comprise neutral enantiomers. 
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Figure 26.1.  Images for 2-azaniumyl-3-(2-hydroxyphenyl)pro-
panoate (DTYROS), 1: chemical diagram (upper view), molecular 
structure \ and overlay diagram. 
 
Figure 26.2 shows images for 4-azido-5-(biphenyl-4-yl)-5-hy-
droxy-3-methyl-2-oxo-2,5-dihydrofuran (2), a neutral molecule crys-
tallising with Z′ = 2 (space-group P21); the R-form is illustrated in the 
molecular diagram [22].  The overlap diagram highlights a close cor-
respondence of the molecular structures in the independent tetrahy-
drofuranyl rings (R- and inverted-S forms) but differences in the ori-
entations of the biphenyl residues. 
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Figure 26.2.  Images for 4-azido-5-hydroxy-3-methyl-5-(4-phe-
nylphenyl)-2,5-dihydrofuran-2-one (DIXPUW), 2: chemical dia-
gram, molecular structure and overlay diagram. 
 
In 3, 2,4-dinitro-2,3-dichloro-3-thiolene-1,1-dioxide, rich in 
heteroatoms, a close overlap is again noted between the five-mem-
bered rings when the molecule in Figure 26.3, i.e. the S-form, is over-
lapped with the inverted form [23].  The molecule crystallises in the 
orthorhombic space-group P212121 with Z′ = 2. 
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Figure 26.3.  Images for 2,3-dichloro-2,4-dinitro-2,5-dihydro-1λ6-
thiophene-1,1-dione (LACFEB), 3: chemical diagram, molecular 
structure and overlay diagram. 
 
 Kryptoracemic behaviour is not restricted to examples with Z′ 
= 2, i.e. two independent molecules in the crystallographic asymmet-
ric unit.  This is illustrated for 1,6-dihydro-1,6-dimethyl-4-phenyl-
1,2,3-triazine 2-oxide (4), where Z′ = 4 (monoclinic, P21); 4 is another 
example of a formally charged species [24].  The asymmetric unit of 
4 comprises two independent pairs of enantiomeric molecules, neither 
of which is related by crystallographic symmetry.  The illustrated 
molecule in Figure 26.4 has the chiral centre being R.  Thus, there are 
one further R-form and two S-forms in the asymmetric unit.  The over-
lap diagram of the two R-forms with the inverted S-forms reveal high 




Figure 26.4.  Images for 1,6-dimethyl-4-phenyl-1,6-dihydro-1,2,3-
triazin-2-ium-2-olate (FATFUB), 4: chemical diagram, molecular 
structure of and overlay diagram. 
 
Molecules of 8-methoxy-1-oxacyclotetradeca-2,13-dione (5) 
have a single stereogenic centre, with the S-form shown in Figure 
26.5.  The kryptoracemate crystallises in the monoclinic space-group 
P21, Z′ = 2 [25].  A centrosymmetric polymorph is also known for 5, 
which exhibits similar unit cell parameters for the space-group P21/c, 
Z′ = 1 [26].  The overlay diagram highlights the close agreement in 
the molecular conformations.  The above observations raise two 
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crucial issues when assessing the aetiology and even the validity of 
kryptoracemic behaviour. 
 
Figure 26.5.  Images for 8-methoxy-1-oxacyclotetradecane-2,13-
dione (NIWHUX), 5: chemical diagram, molecular structure and 
overlay diagram.  In the latter, the blue trace represents the molecule 
found in the centrosymmetric crystal [26]. 
 
The first important issue to be addressed relates to the correct-
ness of the assigned space-group.  In a series of publications spanning 
several decades [28], Marsh and colleagues periodically corrected 
space-group assignments.  Particularly relevant to the present survey 
was the conclusion that the most often missed symmetry in space-
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group assignments, often leading to incorrect or even over-interpreta-
tion of chemistry/correlations with spectroscopy, was the presence of 
a centre of inversion [29].  With modern software, such as PLATON 
[19], it is likely that the number of errant structures will be/should be 
reduced. 
The question of mis-assigned space-groups notwithstanding, 
the second issue arising from the appearance of non-centrosymmetric 
and centrosymmetric polymorphs for 5, remains largely unanswered.  
The crux of this question is: why do kryptoracemates appear in the 
first place?  The centrosymmetric structure of 5 indicates that enanti-
omers of 5 can and do crystallise in a centrosymmetric space-group, 
as might be expected.  So, why the appearance of a non-centrosym-
metric version, the kryptoracemate?  As noted above, kryptorace-
mates crystallise with Z′ > 1; thus far, the author has not come across 
a kryptoracemate with the molecule lying on a rotation axis.  Thus, 
kryptoracemates may be considered a special case of the relatively 
large number of structures with Z′ > 1.  In a recent comprehensive 
review of this topic, Steed and Steed [30] indicate that 9% of all-or-
ganic crystals have Z′ > 1 and include reasons for this phenomenon 
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such as having awkward-shaped molecules, the vagaries of crystalli-
sation techniques, thermodynamics, etc. or some combination of 
these.  In the case of 5, it might be that the observation of the kryp-
toracemic form may be the result of a rapid crystallisation, the kinetic 
form, and the centrosymmetric form, the thermodynamic outcome. 
 Thus far, all of the discussed kryptoracemates discussed fea-
ture a single steroegenic centre only.  However, two and more stereo-
genic centres may be found in kryptoracemates.  An example of a 
kryptoracemate with two stereogenic centres is illustrated for 2,2'-di-
methyl-2,2',3,3'-tetrahydro-1,1'-bicyclopenta(a)naphthalenylidene 
(6) [31] in Figure 26.6.  In the illustrated molecule, both chiral centres 
are R.  As seen above, the superimposition of the illustrated molecule 
with the inverted form shows a close correlation with the exception of 
the relative orientations of the methyl substituents. 
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Figure 26.6.  Images for 2-methyl-1-{2-methyl-1H,2H,3H-cyclo-
penta[a]naphthalen-1-ylidene}-1H,2H,3H-cyclopenta[a]naphthalene 
(AQABID, 6): chemical diagram, molecular structure and overlay di-
agram. 
 
 In 2-[(3,5-dinitrobenzene)amido]cyclobutane-1-carboxylic 
acid (7) [32], the configurations at the sp3-carbon atoms bearing the 
carboxylic acid and amino functionalities are R and S, respectively, as 
shown in Figure 26.7.  The overlap diagram again confirms the close 
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similarity in the molecular conformations, especially in the four-
membered rings.  The presence of carboxylic acid functionality might 
be expected to promote the formation of a racemic crystal whereby 
the carboxylic acid groups of each enantiomer associates about a cen-
tre of inversion via the familiar eight-membered {…HOCO}2 homo-
synthon.  However, while the {…HOCO}2 homo-synthon is formed 
between the two molecules in the crystal (orthorhombic, P212121), the 
homo-synthon is non-symmetric.  It is worth noting here that it is well 
established in the crystallographic literature that carboxylic acids 
form the eight-membered {…HOCO}2 homo-synthon in only about a 
third of the crystal structures where this is possible, being heavily sus-
ceptible to competing supramolecular synthons [33, 34]. 
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Figure 26.7.  Images for 2-[(3,5-dinitrobenzene)amido]cyclobu-
tane-1-carboxylic acid (EGURIH; 7): chemical diagram, molecular 
structure and overlay diagram. 
 
 In another variation of the theme, thus far, all of the chiral cen-
tres have been carbon based.  An attractive exception is found in the 
triphosphatricyclohexadecatriene derivative (8) [35]; the crystal is 
monoclinic, P21.  As seen from Figure 26.8, the two chiral centres are 
phosphorus-based with the configuration being S at the phosphorus 
centre bearing the chloride substituents and R at the second chiral 
phosphorus atom.  Unlike several other structures, differences be-
tween the enantiomers are noted in the conformations of the nine-
membered rings and in the relative orientations of two phenyl rings. 
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Figure 26.8.  Images for 12-chloro-14-N',14-N-diphenyl-
2,6,11,13,15,16- hexaaza-1λ5,12 λ5,14λ5- triphosphatricy-
clo[10.3.1.01,6]hexadeca-1(16),12,14-triene-14,14-diamine 
(GAFJIH; 8): chemical diagram, molecular structure and overlay di-
agram. 
 
 Three chiral centres are noted in the crystal of 1-acetoxy-7-
cyano-5-methylbicyclo(3.2.0)heptan-2-one (9) [36].  For the illus-
trated molecule in Figure 26.9, which crystallises in the monoclinic 
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space-group P21, the configurations at the acetyl, cyano and methyl-
substituted carbon atoms are R, R, and S, respectively. 
 
 
Figure 26.9.  Images for 7-cyano-5-methyl-2-oxobicy-
clo[3.2.0]heptan-1-yl acetate (BINGOU; 9): chemical diagram, mo-
lecular structure and overlay diagram. 
 
 The structure of 6a-ethyl-1-(phenylsulfonyl)decahydro-4H-
pyrrolo(3,2,1-ij)quinoline (10) [36] is notable for two reasons.  First 
and foremost, there are four chiral centres in the molecule, see Figure 
26.10.  The configurations about the centres bearing sulphur and 
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nitrogen atoms are each S while those about the carbon atoms bound 
to three carbon atoms are each R.  Secondly, the crystal structure of a 
stereoisomer is known.  The stereoisomer crystallises in the centro-
symmetric space-group P21/c with Z′ = 1 with equal numbers of all 
S,S,S,R (and R,R,R,S) configurations [37]. 
 
Figure 26.10.  Images for 3-(benzenesulfonyl)-8-ethyl-1-azatricy-
clo[6.3.1.04,12]dodecane (HILXUW; 10): chemical diagram, molecu-
lar structure and overlay diagram. 
 
 Kryptoracemic crystals of the di-hydroxyl species, 1,2,3,4,5,6-
hexahydro-2a,4a-(ethano)cyclopenta(fg)acenaphthylene-3,9-diol 
(11) feature four chiral centres in a monoclinic crystal with space-
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group P21 with Z′ = 4 [38], i.e. with two pairs of crystallographic in-
dependent enantiomeric molecules.  In the molecule illustrated in Fig-
ure 26.11, the two hydroxyl-bearing carbon atoms each has an S-con-
figuration while the other two chiral centres each has a R-
configuration.  Further interest in 11 rests with the observation that a 
polymorph is also known [38].  In this monoclinic crystal, there are 
one and one-half independent molecules in the asymmetric unit (Z′ = 
1.5) with the space-group being P2/c.  While one molecule lies in a 
general position (yellow image in the overlay diagram) while the 
other is located about a two-fold axis of symmetry (pink image).  The 
overlay diagram of the six independent molecules in Figure 11 high-
lights only small conformational differences in the molecules. 
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Figure 26.11.  Images for pentacyclo[5.5.2.21,4.04,14.010,13]hexa-
deca-7(14),8,10(13)-triene-2,15-diol (NOLFUP; 11): chemical dia-
gram, molecular structure and overlay diagram. 
 The are five stereogenic centres in the dibromo derivative, 
1,10-dibromotricyclo(5.2.2.02,6)undeca-4,8-diene (12) [39]; crystals 
belong to the orthorhombic space-group P212121.  In the illustrated 
molecule of Figure 26.12, the chiral centres connecting the five- and 
six-membered rings each have an S-configuration and the remaining 
chiral centres are each R. 
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Figure 26.12.  Images for 7,11-dibromotricyclo[5.2.2.02,6]undeca-
3,8- diene (QEWTES; 12): chemical diagram, molecular structure and 
overlay diagram. 
 
 The final structure to be described among the genuine kryp-
toracemates is that of 4,7;13,16-diepoxy-9,18-dimethyl-1,10-diox-
acyclo-octadecane-2,11-dione (13) [40].  The molecule crystallises in 
the monoclinic space-group P21 and with Z′ = 4; i.e. there are two 
pairs of enantiomeric pairs related across a non-crystallographic cen-
tre of symmetry.  The illustrated molecule of 13 in Figure 26.13 has 
six stereogenic centres, each having a R-configuration.  The overlap 
diagram of the two all R-species with the inverted all S-species show 
a high degree of concordance in molecular conformation. 
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Figure 26.13.  Images for 5,14-dimethyl-4,13,19,20- tetraoxatricy-
clo[14.2.1.17,10]icosane-3,12- dione (NUYTAC; 13): chemical dia-
gram, molecular structure and overlay diagram. 
 
26.3 Non-genuine kryptoracemates 
In this section, representative examples of kryptoracemates with 
additional species incorporated in the crystal are described.  These are 
solvates, salts and crystals with a combination of these.  Enantiomeric 
pairs of chiral molecules are present in all examples as for the genuine 
kryptoracemates reviewed in 26.2 but, so are other species.  In most 
cases it is likely that the presence of additional species does not have 
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a significant influence on the observed kryptoracemic behaviour but, 
as will be demonstrated, certain counter-ions can be employed to 
force the formation of kryptoracemates. 
 The first structure to be described in this section may be con-
sidered the result of an unbalanced crystallisation.  In the crystal of 
trans-2-N,N'-dimethylaminomethyl-1,3-dithiolane-1,3-dioxide (14) 
[41], the chiral centres are the sulphoxide-sulphur atoms, having R- 
and S-configurations in the molecule illustrated in Figure 26.14.  The 
molecule crystallises in the monoclinic space-group P21 with Z′ = 3.  
Two of the molecules have the conformation shown in the molecular 
structure diagram of Figure 26.14, and the third molecule has the op-
posite, i.e. S- and R-configurations.  Hence, there is a deviation from 
the usual 1:1 enantiomeric ratio, and hence, the use of the term “un-
balanced.  In one sense, 14 can be considered a multi-component crys-




Figure 26.14.  Images for 2-[(dimethylamino)methyl]-1λ4,3λ4-di-
thiolane-1,3-dione (VEFMEZ; 14): chemical diagram, molecular 
structure and overlay diagram. 
 
 An analogous situation to 14 pertains in the crystal of 6-(di-
methoxymethylene)-dibenzo(d,k)tricyclo(5.2.2.03,7)undeca-4,10-
dien-8-one (15) [42], which crystallises in the triclinic space-group 
P1 with Z′ = 4.  In this unbalanced crystal, three of molecules have 
the configuration shown in the molecular structure of Figure 26.15, 
i.e. with R-configurations at the three chiral centres, and the fourth 
molecule has the all-S-configuration.  Minor conformational differ-
ences in the orientations of some of the aromatic rings are noted in the 
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overlay diagram (the inverted all-S-configuration is represented by 
the red image). 
 
 
Figure 26.15.  Images for 2-(dimethoxymethylidene)pentacy-
clo[9.6.2.01,9.03,8.012,17]nonadeca- 3(8),4,6,12,14,16-hexaen-18-one 
(SOQQOE, 15): chemical diagram, molecular structure and overlay 
diagram. 
 
 A more conventional co-crystal is evident for 16, having a 2:1 
composition of 3,3-dimethyl-4-(phenylsulfonyl)azetidin-2-one and 
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trans-3-methyl-4-(phenylsulfonyl)azetidin-2-one; 16 crystallises in 
the monoclinic space-group P21 [43].  The illustrated molecule in Fig-
ure 26.16 has an R-configuration around the chiral centre, and the 
overlay diagram between it and its inverted enantiomer suggests a 
conformational difference associated with the relative orientations of 
the phenylsulphoxide residues.  In the molecular packing, each of the 





Figure 26.16.  Images for the 2:1 4-(benzenesulfonyl)-3-
methylazetidin-2-one 4-(benzenesulfonyl)-3,3-dimethylazetidin-2-
one co-crystal (ABADUD; 16): chemical diagram, molecular struc-
ture of 4-(benzenesulfonyl)-3,3-dimethylazetidin-2-one and overlay 
diagram for an enantiomeric pair of 4-(benzenesulfonyl)-3,3-dime-
thylazetidin-2-one molecules. 
 
 The carboxylic acid, syn-1-benzyl-4,5-diphenyl-2-methyl-
4,5-dihydroimidazole-4-carboxylic acid, has been crystallised as its 
hemi-dichloromethane solvate (17) in the orthorhombic space-group 
P212121 [44].  In the molecule illustrated in Figure 26.17, the config-
uration on the carbon atom bearing the carboxylic acid is S and the 
other chiral centre is R.  The overlay diagram is exceptional in that 
there are significant conformational differences in all but the methyl 
substituents about the central five-membered imidazole ring.  In the 
crystal, each of the hydroxyl groups forms an intermolecular hydro-
gen-bonding interaction with an imidazole-nitrogen atom rather than 
self-associating via hydroxyl-O–H…O(hydroxyl) hydrogen-bonding, 
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as has been noted previously in cases of steric congestion [45] and in 
the presence of competing synthons [46]. 
 
Figure 26.17.  Images for 1-benzyl-2-methyl-4,5-diphenyl-4,5-di-
hydro-1H-imidazole-4-carboxylic acid dichloromethane solvate (2:1) 
(KODQOK; 17): chemical diagram, molecular structure of the car-
boxylic acid and overlay diagram for the enantiomeric the carboxylic 
acids. 
 
 Another solvate, this time a 3:2 hydrate is found in the ortho-
rhombic (P212121) crystals of 2,8-diisopropyl-5-trifluoromethyl-7,8-
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dihydro-1,12-iminobenzo(c)pyrido(4,3,2-ef)(1)-benzazepine (18) 
[47].  Just as for 15 and 16 described above, the composition of 18 
can be considered as being unbalanced, with the crystallographic 
asymmetric unit comprising the illustrated molecule in Figure 26.18, 
with an S-configuration at the chiral centre, two inverted organic mol-
ecules along with two water molecules of crystallisation.  Different 
orientations of the isopropyl groups are evident in the overlay dia-
gram.  The independent molecules form different intermolecular in-
teractions.  The molecule with the S-configuration, forms amine-N–
H…N(amine) and N–H…N(pyridyl) hydrogen-bonds.  By contrast, 
each of the two molecules with a R-configuration forms amine-N–
H…O(water) and N–H…N(amine) hydrogen-bonds. 
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Figure 26.18.  Images for the 3:2 8,16-bis(propan-2-yl)-12-(trifluo-
romethyl)-9,15,19-triazapentacyclo[8.7.1.13,17.02,7.014,18]nonadeca-
1(18),2(7),3,5,10,12,14,16-octaene hydrate (AWUVUJ; 18): chemi-
cal diagram , molecular structure of 2,8-diisopropyl-5-trifluorome-
thyl-7,8-dihydro-1,12-iminobenzo(c)pyrido(4,3,2-ef)(1)benzazepine 
and overlay diagram of the organic molecules. 
 
 Attention is now directed towards the description of four salts.  
The first of these, namely the 1:1 salt 2-amino-N-(1-methyl-1,2-
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diphenylethyl)acetamide hydrochloride (19) [48] crystallises in the 
monoclinic space-group P21 with an enantiomeric pair of cations and 
two chloride counter-ions in the asymmetric unit.  The chiral centre 
in the cation shown in Figure 26.19 has a R-configuration.  As noted 
above for 17, non-trivial conformational differences are evident for 
the pendant groups in the overlay diagram.  There is charge-assisted 
ammonium-N–H…Cl and ammonium-N–H…O(carbonyl) along with 
amino-N–H…Cl and amino-N–H…O(carbonyl) hydrogen-bonding op-
erating in the molecular packing.  The independent cations have dis-
tinctive hydrogen-bonding patterns, with the molecule shown in Fig-
ure 26.19 forming ammonium-N–H…Cl and amino-N–
H…O(carbonyl) hydrogen-bonds as opposed to the enantiomer which 
forms two ammonium-N–H…Cl, one ammonium-N–H…O(carbonyl) 
and one amino-N–H…Cl hydrogen-bonding interactions. 
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Figure 26.19.  Images for [(1,2-diphenylpropan-2-yl)car-
bamoyl]methanaminium chloride [MAPXUX; 19]: chemical dia-
gram, molecular structure of the cation and overlay diagram of the 
independent cations. 
 
 A 1:1 ratio between cations and anions is also found in the 
crystal of 2-((2,8-bis(trifluoromethyl)quinolin-4-yl)(hydroxy)me-
thyl)piperidinium 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate 
(triclinic, P1 with Z′ = 2) [49].  The special feature of this structure is 
that the anions are chiral, each have a R-configuration, precluding the 
adoption of a centrosymmetric space-group.  The molecule illustrated 
in Figure 26.20 has two chiral centres, with the carbon bearing the 
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hydroxyl group being S and the other being R.  The overlay diagram 
between this molecule and its pseudo enantiomer mate indicates dif-
ferences in the relative orientations of the piperidinium cations.  The 
hydrogen-bonding interactions formed by the cations are quite simi-
lar, at least to a first approximation, with each of the hydroxyl groups 
participating in a charge-assisted O–H…O hydrogen-bond with a car-
boxylate-oxygen atom.  Each ammonium-N–H atom is bifurcated.  
One hydrogen atom from each ammonium each group forms an intra-
molecular, charge-assisted N–H…O(hydroxyl) hydrogen-bond and 




Figure 26.20.  Images for 2-{[2,7-bis(trifluoromethyl)quinolin-4-
yl](hydroxy)methyl}piperidin-1-ium 3,3,3-trifluoro-2-methoxy-2-
phenylpropanoate [ENIPUO; 20]: chemical diagram, molecular struc-
ture of one cation and overlay diagram of the cations. 
 
 The next structure to be described is also a 1:1 salt, i.e. bis(2-
((2,8-bis(trifluoromethyl)quinolin-4-
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yl)(hydroxy)methyl)piperidinium) chloride 4-fluorobenzenesulfonate 
(orthorhombic, P212121 with Z′ = 2) [50].  The key difference in this 
case is that the two anions are distinct.  For the molecule illustrated in 
Figure 26.21, the chirality of the carbon connected to the hydroxyl 
group is R and the other chiral centre in the ring is S.  As for 20, there 
is a minor conformational difference in the piperidinium cations.  De-
spite the presence of distinct anions, the hydrogen-bonding interac-
tions at play in the crystal are comparable.  Thus, each hydroxyl 
groups forms a hydrogen-bond to a sulphoxide-oxygen atom, indeed 
to the same atom.  The two ammonium-N-H atoms of each cation 




Figure 26.21.  Images for 2-{[2,7-bis(trifluoromethyl)quinolin-4-
yl](hydroxy)methyl}piperidin-1-ium chloride 4-fluorobenzene-1-sul-
fonate [ELAMAH, 21]: chemical diagram, molecular structure of one 
cation and overlay diagram. 
 
 The crystal of 21 is the second 2-{[2,7-bis(trifluorome-
thyl)quinolin-4-yl](hydroxy)methyl}piperidin-1-ium salt to be de-
scribed.  These species are of interest as the R,S-cation, as its chloride 
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salt, commonly known as mefloquinium chloride, was found to be ef-
fective against malaria [51].  The salts 20 and 21 were prepared in 
attempts to resolve the enantiomers as the S,R-enantiomer causes 
toxic side-effects and, in fact, were the structures that piqued the in-
terest of the author in this field.  Of the about 30 known [4] crystal 
structures of methloquine/mefloquinium, two are kryptoracemic.  In 
another study [52], where crystallographic details were reported only 
extremely briefly, it was mentioned that in their attempts at chiral res-
olution, about the same ratio of kryptoracemates were isolated.  These 
numbers exceed greatly the estimated 0.1% frequency for this behav-
iour and may suggest a propensity of these molecules towards kryp-
toracemic behaviour.  However, it is more likely that the “McCrone 
axiom” is apt here [53]: paraphrasing, the more effort one puts into 
discovering different forms of crystals, the more likely it is that new 
forms will be discovered.  This axiom is clearly vindicated by com-
putational chemistry investigations which indicate that many calcu-
lated polymorphic forms of a molecule may differ in Gibbs free ener-
gies by only a few kcal/mol [54, 55]. 
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 One last kryptoracemate example is included for the sake of 
completeness, namely a salt solvate, cis-2-phenyl-3-methoxycar-
bonyl-pyrrolidinium oxalate hemihydrate (22) [56].  The crystallo-
graphic asymmetric unit in the monoclinic space-group P21 comprises 
two cations, two anions and a water molecule of crystallisation.  The 
cation represented in Figure 26.22 has S- and R-configurations at the 
carbon atoms carrying the phenyl and ester groups, respectively.  As 
is normally the case, the agreement in conformation between the il-
lustrated and inverted mate is close as seen in the overlay diagram.  
The hydrogen-bonding profiles exhibited by the cations are quite sim-
ilar with one ammonium-N–H atom of each forming a donor interac-
tion to the water molecule of crystallisation.  In the same way, the 
second ammonium-N–H atom of each cation is bifurcated.  For the 
illustrated molecule in Figure 26.22, this atom bridges the carbonyl-
oxygen atom of the carboxylic acid group and a carboxylate-oxygen 
atom of the same oxalate anion, thereby forming a five-membered 
{H…OCCO} synthon.  A slight difference occurs in the case of the 
second cation.  Although a five-membered {H…OCCO} synthon is 
still formed, one, weaker, hydrogen-bond involves the hydroxy group 
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of the oxalate anion (rather than a carbonyl) resulting in a significantly 
longer N–H…O hydrogen-bond. 
 
Figure 26.22.  Images for 3-(methoxycarbonyl)-2-phenylpyrroli-
din-1-ium hydrogen oxalate hemihydrate [FAHQUB; 22]: chemical 
diagram, molecular structure of one of the cations and overlay dia-
gram of the cations. 
 
26.4 Overview 
The intention of the present survey of reported kryptoracemic crys-
tals highlights the structural diversity of this rare class of crystal, 
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making up only 0.1% of all-organic crystals [3].  The genuine or pure 
kryptoracemates – containing pseudo-racemic pairs only – have mol-
ecules related about a non-crystallographic centre of symmetry with 
only minor conformational differences.  Similar observations pertain 
to non-genuine kryptoracemates which contain additional species 
(solvent and counter-ions) in their crystals in addition to pseudo-race-
mic pairs.  Kryptoracemates can only crystallise in Sohncke space-
groups and the overwhelming majority of genuine examples crystal-
lised in three space-groups: P1 (15%), P21 (52%) or P212121 (33%).  
For the non-genuine kryptoracemates, a possible reason for this be-
haviour may relate to the presence of additional species and the influ-
ence these have on the supramolecular association operating in the 
crystals, something unlikely to “pertain” in the genuine kryptorace-
mates. 
At present, it is probably fair to opine that most of the reported 
kryptoracemates are the product of serendipity and that systematic 
studies are likely to uphold the McCrone axiom [53] but, prove to be 
most rewarding at the same time [57].  Certainly, a rationale of this 
45 
behaviour will prove useful in the understanding of the crystallisation 
phenomenon in general. 
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